CJC-1295 (No DAC)
Mod GRF 1-29. Short-acting GHRH analogue for pulsatile GH release. The ideal partner for Ipamorelin.
Last updated: June 2026
Category
Growth Hormone
Frequency
1 to 3x daily (community practice, no trial)
Research
Research GradeWhat is CJC-1295 (No DAC)?
CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a truncated, stabilized form of GHRH (Growth Hormone Releasing Hormone) with a half-life of approximately 30 minutes. Unlike CJC-1295 with DAC, it does not bind to albumin and is cleared relatively quickly from the body. Browse the full peptide library for related GH compounds.
This shorter half-life means it produces a sharp, pulsatile GH release that more closely mimics the natural pattern of GH secretion, a burst every few hours. When combined with Ipamorelin (which activates the GH secretagogue receptor), the two peptides work synergistically to produce significantly higher and more sustained GH pulses than either can achieve alone.
CJC-1295 (no DAC) + Ipamorelin is considered the gold-standard GH protocol in the peptide community. It's favored for its physiological GH pattern, excellent tolerability, and the ability to time doses strategically (pre-sleep, pre-workout). For FDA-approved visceral fat reduction specifically, see tesamorelin.
How It Works
GHRH Mimicry: Binds to GHRH receptors in the pituitary, signaling it to release stored GH. Acts like a "command" signal.
Short Half-Life Advantage: The ~30 minute half-life means each dose creates a clean GH pulse that rises and falls naturally, mimicking physiological GH patterns rather than creating a sustained bleed.
Ipamorelin: CJC (no DAC) signals the pituitary through the GHRH receptor while ipamorelin acts through the ghrelin receptor. Those are two separate signals, which is the mechanistic reason the pair gets discussed, but no published trial has measured GH output from the two given together, so the size of any combined effect is not known.
Benefits
- Natural pulsatile GH release pattern
- Commonly paired with Ipamorelin in community practice (no trial has tested the combination)
- Strategic timing possible (sleep, workout)
- Less water retention vs CJC with DAC
- Improved sleep, recovery, and body composition
- Lower risk of pituitary desensitization vs DAC version
Dosing Described in Research and Labels
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| GH secretagogue (research) | No established human dose | Subcutaneous (research) | Not established |
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Side Effects
Common
- ⚠Mild water retention (less than DAC version)
- ⚠Tingling in hands/feet
- ⚠Mild hunger increase
- ⚠Headache in first week
Rare
- •Hypoglycemia
- •Pituitary desensitization with very high doses
Who Should NOT Use CJC-1295 (No DAC)
- ✕Active cancer
- ✕Diabetic retinopathy
- ✕Pregnancy or breastfeeding
What to Expect
Improved sleep quality is often the first sign. Mild water retention possible.
Faster recovery. Better body composition. Skin quality improving.
Clear anabolic and fat-loss effects when combined with training and diet.
A roughly 4 week break before repeating is the commonly reported pattern (community practice, no trial). No trial has established a cycle length and no approved label defines one.
Notes from Ho Chi Minh City
The CJC no-DAC plus Ipamorelin pairing is the GH-secretagogue stack the HCMC scene treats as a year-round staple, run in cycles rather than continuously. The rationale the research supports is that the GH pulse during slow-wave sleep is where most of the recovery and skin-quality benefit sits, which is why the pairing is timed around sleep and a fasted window. The no-DAC version is generally preferred over the DAC form here because it gives a cleaner pulse without the water retention that DAC plus HCMC heat produces. Handling matters: reconstituted peptide needs bacteriostatic water from a verified supplier and refrigeration, since sterile water alone leaves too short a shelf life to be practical. Dose, timing, and stack design are decisions for a licensed prescriber, not a fixed forum protocol.
FAQ
Q: Do I need to use CJC (no DAC) and Ipamorelin together?
A: No trial has tested CJC-1295 without DAC alongside ipamorelin in people, so the claim that the combination is significantly more effective, or that it is the minimum worth running, has nothing measured behind it. The mechanistic reason the two get discussed together is real enough to state: they act at different receptors, GHRH and ghrelin. That describes two signals, not a demonstrated result. Neither compound is approved in any market, so there is no label defining a combination either. What has been measured is CJC-1295 alone: single subcutaneous doses in healthy adults raised growth hormone 2 to 10 fold and IGF-I 1.5 to 3 fold, with a half-life of 5.8 to 8.1 days for the long-acting DAC form (human trial, not a recommendation, PMID 16352683). Whether either compound belongs in use at all is a decision for a licensed prescriber.
Q: How many times per day should I dose?
A: Frequency follows from the short half-life rather than a set rule: because the no-DAC form clears quickly, the variables people discuss are timing relative to sleep and whether to add a daytime dose, and a fasted state is where the research describes GH release as least blunted by insulin. How many doses, and when, are decisions for a licensed prescriber, not a forum default. Source from the community-verified supplier list.
Where to Get CJC-1295 (No DAC) in Vietnam
See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.
Related Peptides
Related Guides
Research & Sources
- Effects of an analog of growth hormone-releasing factor on GH secretion in normal human subjects · Jette L, Leger R, Thibaudeau K, et al. · Endocrinology (2005) (PMID: 15919742)
Pharmacokinetic and pharmacodynamic data underlying the short half-life advantage of Mod GRF 1-29.
- Determinants of GH-releasing hormone and GH-releasing peptide synergy in men · Veldhuis JD, Bowers CY · American Journal of Physiology: Endocrinology and Metabolism (2009) (PMID: 19240251)
Demonstrates the synergistic GH release when GHRH analogues are combined with GH secretagogues like ipamorelin.
- A quantitative estimation of growth hormone secretion in normal man: reproducibility and relation to sleep and time of day · Van Cauter E, Kerkhofs M, Caufriez A, et al. · The Journal of Clinical Endocrinology and Metabolism (1992) (PMID: 1592892)
Defines the natural pulsatile GH pattern that the CJC no-DAC plus ipamorelin protocol attempts to replicate.
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse · Alba M, Fintini D, Sagazio A, et al. · American Journal of Physiology: Endocrinology and Metabolism (2006) (PMID: 16822960)
Compares DAC vs non-DAC CJC-1295 forms to clarify the trade-off between sustained vs pulsatile GH release.
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.